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TCT-481
Diastolic Heart Failure – Innovative Extra and Intra Ventricular Solutions
Mitchell W Krucoff2, Lea Lak1
1CorAssist CardioVascular, Herzliya, Israel; 2Duke University Medical Center/Duke
Clinical Research Institute, Durham, NC
Background: Diastolic heart failure (DHF) accounts for over 40% of HF cases. Proven
evidence based treatment is lacking. A novel mechanical approach, utilizing energy
exerted by the left ventricle (LV) during systole and returning it to the ventricle during
diastole to enhance diastolic performance, was realized in two approachs: An Extra-
ventricular device (ImCardia™), comprised of elastic springs attached to the LV
epimyocardium. A trans apically delivered Intra-ventricular device (CORolla™)
comprised of a three-arms spring.
Methods: The ImCardia™ device was implanted as an add-on to AVR (study group,
n=10), and compared to AVR only (control group, N=9). The patients were followed
up to 24 months to examine indications of safety and efficacy. The CORolla™ device
was implanted off-pump in trans-apical approach in healthy sheep (N=26). The sheep
were followed up to 9 months. Device acute and chronic safety was evaluated.
Results: ImCardia™: During follow-up period there were no device-related
complications or adverse events. Improvement in NYHA functional class, 6-minute
walk test and quality of life were similar for both groups. LV mass regression after 18-
24 months: -90 gr ± 82 gr in control group Vs -126 gr ± 33 gr in study group. Left
atrial area, an important marker of diastolic dysfunction, increased slightly in control
group (+1.5 cm2 ± 4.09 cm2) but decreased in study group (-2.29 cm2 ± 3.09 cm2).
CORolla™: good recuperation post implantation with no weight reduction, no EF
reduction, good device functionality and safety in follow-up up to 9 months.
Conclusion: A passive extra-cardiac device which transfers energy from systole to
diastole, may improve diastolic performance as suggested by further decrease in left
atrial size beyond that expected from AVR only; not only the device did not induce LV
hypertrophy, it rather demonstrated a trend of LV mass regression enhancement. Using
this methodology, an Intra-ventricular elastic device implanted transapically off-pump
demonstrated safe profile. Clinical study is planned to start toward end 2011.
Percutaneous approach for the intra-ventricular device is in R&D process.
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Clinical and Angiographic Results of PROTECT II
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Houston, TX; 3William Beaumont Hospital, Royal Oak, MI; 4Harvard Clinical
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Wormleysburg, PA; 6University of Pittsburgh Medical Ctr., Pittsburgh, PA;
7Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands;
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Lake City, UT; 10Sanger Heart & Vascular Institute - University of NC, Charlotte,
NC; 11Columbia University Medical Center, New York City, NY; 12Duke University,
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Background: To investigate the potential benefit of Impella 2.5 in high-risk PCI
(HRPCI) compared to the intra-aortic balloon-pump (IABP) in a prospective
multicenter clinical trial.
Methods: The PROTECT II trial was designed to randomize 654 HRPCI patients who
required prophylactic hemodynamic support to Impella or IABP. Patients with 3-vessel
disease and LV ejection fraction (LVEF) ≤30%, or with unprotected left main or last
patent conduit and LVEF ≤35% were eligible for enrollment. Selection of the
revascularization approach was at the discretion of the PCI operator. The primary
endpoint was a composite of 10 major adverse events (MAE) at 30 days with a follow-
up at 90 days.
Results: Enrollment began in late 11/2007 and reached the 50% mark (n=327) by
02/2010. After pre-specified review of the 50% enrollment data, the Data Safety
Monitoring Board recommended termination of the study due to futility on the 30-day
primary analysis. At the time of the recommendation (11/2010), the study had reached
68% of the planned enrollment (N=447). The preliminary analysis showed a significant
learning curve with Impella, with outcomes improving over the course of the trial.
There was a trend for better outcomes at 30 days in favor of Impella for the entire per
protocol population (p=0.10). At the 90-day pre-specified follow-up, there was a
significant reduction in MAE in favor of Impella (p=0.03, see Figure). The final new
clinical and angiographic results of the entire cohort will be presented.
Conclusion: PROTECT II was terminated early on assumptions based on the first half
of the data. The analysis of the full cohort provides more insight into the study and
suggests positive outcomes over time for the Impella compared to the IABP with a
similar safety profile.
TCT-483
Is It Appropriate To Take All Post-Resuscitation Patients Suspected of Having
an Acute MI For Urgent Angiography?
Vivek K Reddy, Vinay R Hosmane, Andrew Doorey, William S Weintraub, Ehsanur
Rahman
Cardiology, Christiana Care Health Systems, Newark, DE
Background: Recent studies of patients who have been resuscitated from out-of-
hospital cardiac arrest (OHCA) have shown increasing benefit from timely reperfusion
therapy for those with STEMI as the etiology. Though no randomized trials have been
performed, patients with OHCA with early reperfusion for concurrent STEMI have a
mean survival rate of 65%, compared to historical survival of only 25% to 35% for
those with only OHCA. The addition of early hypothermia to early reperfusion results
in significantly improved neurological function. We reviewed our data to see if OHCA
patients who do not fit these criteria were undergoing urgent angiography
inappropriately.
Methods: Our facility is a large, academic, community center with around-the-clock
catheterization capabilities for STEMI. We retrospectively examined our internal
databases of consecutive patients suspected of having STEMI between January 1, 2001
and December 31, 2010. Further data was obtained from electronic hospital records,
emergency department records, paramedic records, and the cardiac catheterization
database.
Results: Between January 1, 2001 and December 31, 2010, there were 3908
consecutive patients who were suspected of having an MI, 409 of which required CPR.
Of these, 240 underwent emergent angiography. In 191 patients a culprit lesion was
identified, but in 49 (20%) no culprit lesion was seen. Review of the pre-cath EKGs
showed no definitive ST-elevation in 26 of 49 patients (53%). Ventricular fibrillation
or tachycardia was the presenting rhythm in 34 patients (69%). During their
hospitalization, 26 patients (53%) died.
Conclusion: Even though the favorable outcomes in the available literature are based
on STEMI concurrent with OHCA, a significant number of patients who do not have
ST-elevation on post-resuscitation EKG are undergoing cardiac angiography
emergently. Other measures such as stabilizing hemodynamics, controlling rhythms,
and, perhaps most importantly, early initiation of hypothermia are probably more
important at this stage when the EKG does not show ST-elevation.
TCT-484
Cost-effectiveness and Clinical Outcomes of Impella Hemodynamic Support
Compared with Intra- Aortic Balloon Pump in High Risk Patients Receiving
PCI: Results from the PROTECT II Trial
Brijeshwar Maini1, William O’Neill2, Simon Dixon4, Igor Palacios3, Theodore
Schreiber5, David A Gregory6, D. J Scotti6
1PinnacleHealth Cardiovascular Institute, Wormleysburg, PA; 2University of Miami,
Miami, FL; 3Beaumont Hospital, Royal Oak, MI; 4Massachusetts General Hospital,
Boston, MA; 5Detroit Medical Center, detroit, MI; 6Presscott Associates, Ltd., Avon,
CT
Background: Clinical outcomes and cost-effectiveness of new technologies for
hemodynamic support in patients with left ventricular dysfunction and complex
anatomy have not been previously studied.
Methods: PROTECT II studied patients with 3 vessel disease and LV ejection fraction
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≤ 30% or with unprotected left main/last patent conduit and LV ejection fraction ≤ 35%
during PCI. Patients were randomized to either intra aortic balloon pump (IABP) or
Impella (Abiomed). The primary endpoint was a composite of ten major adverse events
(MAE) measured at 30 and 90 days. Economic analyses were performed to assess
resource utilization for patients treated with Impella compared to IABP from index
stay up to 90 days. Itemized hospital bills were collected for U.S. patients that
consented for the economic study (N=260), converted to costs using department level
cost-to-charge ratios, and modeled for the complete trial patient population at 90 days.
Estimated costs were validated via comparison with MedPAR. Measures of episode-
of-care costs, major adverse cardiac and cerebral events (MACCE), and
Quality-Adjusted Life Years (QALYs) for both study arms served as inputs to a Markov
model to estimate the incremental cost-effectiveness ratio (ICER).
Results: MAE at 90 days for Impella were 40.8% vs. IABP 51.4% (p=0.029) including
a 51% relative reduction in repeat revascularization (Impella 6.1% vs. IABP 12.4%,
p=0.026). For the economic study, index hospital costs were lower in the IABP arm
while readmission costs and length of stay were lower in the Impella arm. Median
hospital days for entire episode-of-care for Impella were 7 days vs. IABP 9 days
(p=0.048). Reduction in MAE was associated with a gain in QALY for Impella patients.
Base case ICER was well below the $100,000 value often given as a threshold for
innovative technologies.
Conclusion: For patients with severe LV dysfunction and complex anatomy,
prophylactic use of Impella during PCI reduced MAE at an incremental cost per
quality-adjusted life year considered to be cost-effective for advanced cardiovascular
technologies. Reductions in repeat revascularizations, readmission costs and length of
stay may have significant health policy implications.
TCT-485
Aspiration of The Blood From The Left Ventricular cavity to Treat Refractory
Ventricular Arrhythmias During Complex Coronary Interventions
Waleed Y Kadro, Maya Turekmani, Hussam Rahim, Ali Dbs, Ismael Eid
Interventional Cardiology, The Golden Cardiovascular Center, Damascus, Syrian
Arab Republic
Background: Ventricular fibrillation (VF) may happen during complex coronary
intervention due to wire or catheter manipulation, balloon inflation or reaction to the
contrast. This can be treated easily with prompt cardioversion; however some of VF
may become refractory especially in the cases of severe ischemic burden, elevated left
ventricular filling pressure (LVEDP) or reduced left ventricular function.
Methods: We report a new simple quick method to reduce LVEDP by inserting a
catheter (e.g a pigtail or JR) inside the left ventricle (LV) and doing quick manual
aspiration of 80-100cc of blood from the LV cavity. This will quickly reduce the
LVEDP and make refractory VF easily responsive to cardio version. It can also provide
a simple decompression of the overfilled LV after prolonged circulatory arrest.
Results: This method was used in 8 cases of refractory VF. Five of them failed 3
attempts of DC cardioversion despite recanulization of the diseased artery. After doing
this maneuver, those five cases responded immediately to the next attempt of
cardioversion. Three other cases of VF responded to cardioversion with electrical sinus
rhythm however the 3 patients remained pulseless in electromechanical dissociation
(EMD), no arterial pressure and no cardiac movement on fluoroscopy. Despite ruling
out tamponade and mechanically treating cardiac ischemia the two patients remained
in EMD. After doing the pigtail maneuver EMD resolved and active cardiac movement
were seen on fluoroscopy with acceptable arterial pressure recovery. All of these 8
patients survived till hospital discharge.
Conclusion: Quick insertion of a catheter in the LV with quick blood aspiration
facilitates response to cardioverion and may relief EMD not related to tamponade
during coronary intervention. It looks that the interventional cardiologists need this
simple way of LV venting in the cath lab.
TCT-486
Medical Treatment and Coronary Angioplasty in Patients with Severe Left
Ventricular Dysfunction and Coronary Artery Disease
Diego David Grinfeld, Florencia Rolandi, Pablo Pollono, Ignacio Rifourcat,
Fernando Fuertes, Jose Luis Parmisano, Ricardo Pastene, Liliana Grinfeld
Hospital Espanol de La Plata-Idytac, La Plata, Argentina
Background: Background: Coronary artery disease (CAD) is the cause of Ventricular
Dysfunction and Heart Failure (HF) in the majority of patients (pts), and HF is the
only mode of CAD presentation associated with increasing incidence and mortality.
Among a large number of patients there is no evidence about witch therapeutic strategy
is better, so a large number of patients how could be beneficiated by a Coronary
Angioplasty with Stent (PCI) receive medical treatment.
Methods: Methods: Between June 2005 and December 2010 we performed 3450
consecutives coronary angiographies, among those pts 255 (7.4%) have had
LVEF<35% and coronary disease. We divide the pts en 2 groups: MT and PCI.
Results: Results: population: age 66.8 ± 9.4 years, 84% male, 80.3% hypertension,
35.2% diabetes, 72.9% lipid disorders, 12.8% smokers, 55.6% ex-smokers, 26.5% with
familiar history of CAD, 62.3% with previous AMI, 3.1 % previous Stroke, 15.2%
previous PCI and 25.6% previous CABG. One out of 5 pts were hospitalized in the
last year because of HF. At baseline 46.6% of the pts were in dyspnea FC III-IV; 11.2%
in FC I-II and 42.2% were asymptomatics. Only 54 % of the total population received
complete Medial Treatment (MT) (bet blockers, enalapril and diuretics). Multivesel
disease was present in 55.8% of the pts. CABG were performed in 28 pts (10.9%), PCI
in 135 pts (52.9%), in 65 pts a MV PCI was performed. Drug eluting stents (DES)
were used in 63.2% of PCI. The others 92 pts (36.1%) continues with MT. Twelve (12)
pts received definitive pace-maker and 10 pts. ICD. Total mortality was 13.5%, no
significant differences were found among groups. At follow-up pts who underwent
PCI showed an statistically significant diminution in dyspnea FC from III-IV to I-II
and other symptoms (FC I-II 21.7% vs. 66.0% post PCI, p<0.0001 and FC III-IV 73.3%
vs. 7.6% post PCI, p<0.0001, asymptomatics 5.0% vs. 26.4 at F/U, p 0.002) compared
with MT group pts (FC I-II 0% vs. 17.9%, p- y FC III-IV 13.9% vs. 7.7% at FU, p
0.37; asymptomatics 86.1% vs. 74.4% at F/U, p 0.18). In the CABG group
asymptomatics pts were 69.2% pre CABG and 63.6% at FU, p 0.8.
Conclusion: Conclusion: in pts with severe left ventricular dysfunction (LVEF <35%)
and CAD, PCI improved symptoms and there after quality of life and don’t increase
mortally at long term Follow up.
TCT-487
Coronary Sinus Technique in End Stage Heart Failure
Jorge Tuma1, Roberto Fernández1, Carlos Cruz1, Alvaro Carrillo1, José Ercilla1, Luis
Inga1, Carlos Yarleque1, Jaime Cunza1, Samuel Chirinos1, Jorge Castillo1, Antonio
Carrasco1, Amid Patel2
1Center for Interventional Cardiology and Institute of Autologous Stem Cell, Inacel
Maison de Santé Clínic, Lima, Peru; 2The University of Utah, Utah, UT
Background: Randomized studies suggest that intracoronary transplantation of
autologous cells may improve Left Ventricular Ejection Fraction (LVEF) in heart
failure (HF).
Methods: 77 patients were enrolled and completed 5 years follow up. Patients
underwent SPECT evaluation; all had LVEF ≤ 25%, 40 patients with isquemic HF
(IHF) and 37 patients with non-isquemic HF (nIHF). For IHF and nIHF at baseline:
the median age was 67 and 64 years old respectively (ns); NYHA III/IV were 31/9 and
29/8 respectively (ns); median LVEF were 18.7% and 24.7% respectively (ns); median
EDV were 281 ml and 242 ml respectively (p=0.16, ns) and median ESV were 217 ml
and 189 ml respectively (p=0.29, ns). Median numbers of MNC & CD34+ cells were
12*108 & 23*106 respectively. Cells were delivered in 90 cc using a retrograde
technique by coronary sinus approach using a balloon occlusion “over wire” for 10 to
15 minutes. No early or late study related adverse events were observed.
Results: After a median time of 21 days, patients in both groups had relief of dyspnea
symptoms and improvement in functional class. All patients were evaluable at one year
and 32 and 30 in each group for 5 years follow-up. Differences (Δ) and statistic
difference (p) are shown in the table:
Results
Conclusion: Infusion of autologous bone marrow cells into the coronary vein is safe
and feasible. It is associated with significant improvement in symptoms and functional
capacity benefit. Both groups benefited in terms of LVEF improvement and lower ESV.
Our data suggest that nIHF patients have a higher LVEF increment than IHF patient
and lasting up to 5 years; revealing a high restoration of myocardial dysfunction.
Further randomized studies are warranted.
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